Provectus Biopharmaceuticals, Inc. (OTCQB:PVCT) (http://www.pvct.com),
a development-stage oncology and dermatology biopharmaceutical company,
announced today that data on PV-10 for cutaneous melanoma will be
included in a session at HemOnc Today – Melanoma and Cutaneous
Malignancies Conference. HemOnc Today will be held this year at the
Sheraton New York Times Square in New York City on Friday, April 11 and
Saturday, April 12, 2014.
Dr. Robert H.I. Andtbacka, associate professor in the Division of
Surgical Oncology, Department of Surgery at the University of Utah
School of Medicine, will moderate Session 4: Local and Regional Therapy.
Session 4 will be held on Friday, April 11 at 2:15 pm. Sanjiv S.
Agarwala, MD, Program Director of the Conference, has said data
regarding “PV-10 will be an integral part of session 4.”
Provectus has recently submitted an application to the FDA for
breakthrough therapy designation for PV-10 based on the results from its
Phase 2 clinical study.
Craig Dees, PhD, CEO of Provectus said, "We are very pleased to have our
data form such a significant part of this important, cutting-edge
conference.”
About Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals specializes in developing oncology and
dermatology therapies. Its novel oncology drug PV-10 is designed to
selectively target and destroy cancer cells without harming surrounding
healthy tissue, significantly reducing potential for systemic side
effects. Its oncology focus is on melanoma, breast cancer and cancers of
the liver. The Company has received orphan drug designations from the
FDA for its melanoma and hepatocellular carcinoma indications. Its
dermatological drug PH-10 also targets abnormal or diseased cells, with
the current focus on psoriasis and atopic dermatitis. Provectus has
recently completed Phase 2 trials of PV-10 as a therapy for metastatic
melanoma, and of PH-10 as a topical treatment for atopic dermatitis and
psoriasis. Information about these and the Company's other clinical
trials can be found at the NIH registry, www.clinicaltrials.gov.
For additional information about Provectus please visit the Company's
website at www.pvct.com
or contact Porter, LeVay & Rose, Inc.
FORWARD-LOOKING STATEMENTS: The forward-looking statements contained
herein are subject to certain risks and uncertainties that could cause
actual results to differ materially from those reflected in the
forward-looking statements. Readers are cautioned not to place undue
reliance on these forward-looking statements, which reflect management's
analysis only as of the date hereof. The company undertakes no
obligation to publicly revise these forward-looking statements to
reflect events or circumstances that arise after the date thereof.
Copyright Business Wire 2014